INmune Bio's unique Alzheimer's trial endpoint receives validation

By Yahoo! Finance | Jun 28, 2024 at 01:32 PM EST

INmune Bio's AD02 trial for Alzheimer's disease, using TNF XPro with EMACC as the primary endpoint, shows positive results after FDA clinical hold. The trial's efficacy in assessing cognitive function in early Alzheimer's stages is validated, advancing potential treatment options.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.